Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma
Table 3
(a) Biomarker expression in healthy women and patients in phases I (prior to surgery) and II (after treatment) was compared and value was calculated
Healthy women
Patients (phase 1)
Patients (phase II)
value
Biomarker expression
N
%
N
%
N
%
Phase I compared to healthy women
Phase I compared to phase II
CK19
22
73
28
93
17
56.6
0.012
≤ 0.001
hMAM
18
60
17
56
17
56.6
NS
—
HER2
0
0
0
0
0
0
—
—
MUC1
28
93
30
100
30
100
NS
—
Myc
10
33
15
50
4
13.3
0.023
≤ 0.001
Ki-67
19
63
25
83
13
43.3
0.012
≤ 0.001
ErbB2
12
40
15
50
15
50
NS
—
ER
19
63
20
67
17
58.3
NS
NS
CEA
11
36
15
50
14
46.6
0.043
NS
N: number of subjects; value ≤ 0.05 was considered statistically significant; NS: not significant.
(b) Biomarker expression in phases I (prior to surgery) and II (after treatment) and its correlation with the stage of disease was compared in patients and value was calculated
Biomarker expression
Phase I
Phase II
Stage I
Stages II/III
value
Stage I
Stages II/III
value
N
%
N
%
N
%
N
%
CK19
11
39
17
61
NS
5
29
12
71
NS
hMAM
10
59
7
41
0.004
9
53
8
47
0.034
HER2
0
0
0
0
—
0
0
0
0
—
MUC1
11
37
19
63
—
11
37
19
63
—
Myc
10
67
5
33
0.001
2
50
2
50
—
Ki-67
11
44
14
56
NS
8
60
5
40
0.013
ErbB2
10
67
5
33
0.001
0
0
15
100
≤0.001
ER
10
50
10
50
—
10
57
7
42.9
0.004
CEA
8
53
7
47
0.058
8
57
6
42.9
0.029
N: number of positive subjects; %: positivity percentage; value ≤ 0.05 was considered statistically significant; NS: not significant.
